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The initiation and progression of various solid tumors, including pancreatic carcinoma, are driven by a population
of cells with stem cell properties, namely cancer stem cells (CSCs). Like their normal counterparts, CSCs are also
believed to rely on their own microenvironment termed niches to sustain the population. Hypoxia-inducible factor-1α
(HIF-1α) is a major actor in the cell survival response to hypoxia. Recently, several researchers proposed that non-stem
cancer cells can convert to stem-like cells to maintain equilibrium. The present study focuses on whether non-stem
pancreatic cancer cells can convert to stem-like cells and the role of HIF-1α and autophagy in modulating this
conversation. The non-stem pancreatic cancer cells and pancreatic cancer stem-like cells were separated by
magnetic sorting column. Intermittent hypoxia enhanced stem-like properties of non-stem pancreatic cancer
cells and stimulated the levels of HIF-1α, LC3-II and Beclin. Enhanced autophagy was associated with the elevated
level of HIF-1α. The conversation of non-stem pancreatic cancer cells into pancreatic cancer stem-like cells was induced
by HIF-1α and autophagy. This novel finding may indicate the specific role of HIF-1α and autophagy in promoting the
dynamic equilibrium between CSCs and non-CSCs. Also, it emphasizes the importance of developing therapeutic
strategies targeting cancer stem cells as well as the microenvironmental influence on the tumor.
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Pancreatic cancer is the fourth leading cause of cancer-
related death in the United States. It is characterized by
rapid progression, early metastasis, and a limited response
to chemotherapy [1]. Despite advances in our understand-
ing of the molecular biology of pancreatic cancer, the out-
come of systemic treatment for this disease remains
unsatisfactory. Inhibition of tumour growth and metasta-
sis by inhibitors of matrix metalloproteinases and angio-
genesis had little effect on the natural progress of this
malignancy and did not produce dramatic improvements* Correspondence: zhht25@126.com; gbshao07@mail.ujs.edu.cn
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stated.in patient survival rate [2,3]. More understanding of
molecular mechanisms of cell growth and proliferation
is urgently needed.
A distinct population of cancer cells, namely cancer
stem cells, had been defined and characterized in several
human cancers, including pancreatic cancer [4-6]. Most
described CSCs were isolated from solid tumors based
on the expression of surface markers [7,8]. CD133 is a
marker protein typically used to identify and isolate hu-
man pancreatic CSCs [9]. The properties that distinguish
CSCs from the rest of the tumor cells are their ability to
self-renew, differentiate into heterogeneous types of
tumor cells, and sustain tumor growth in vivo [10]. In
this study, we designated CD133 positive cells as pancre-
atic cancer stem-like cells whereas CD133 negative cells
utilized as non-stem pancreatic cancer cells. Due to fail-
ing to eradicate the CSCs population, traditional cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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fail to produce long-term clinical complete remissions. A
number of studies in recent years have demonstrated that
CSCs are located in specialized microenvironments within
tumor [11-13].
Most solid tumors are characterized by hypoxic areas
originating from an imbalance between oxygen supply
and expenditure in the actively proliferating tumor
cells. It is becoming increasingly clear that the intrinsic
properties of CSCs are tightly regulated by specific
hypoxic microenvironments. Interestingly, several re-
searchers proposed that differentiated cancer cells (non-
stem cancer cells) can convert to stem-like cells to maintain
equilibrium [14-16]. However, the exact mechanisms of
how hypoxic niches induce non-CSCs into CSCs remain
largely unknown.
In this study, we first examined the role of intermittent
hypoxia in converting the non-stem pancreatic cancer
cells into pancreatic cancer stem-like cells. Then, we ex-
amined the effective of intermittent hypoxia in changing
expression levels of HIF-1α, LC3-II and Beclin. Finally,
we tested the relation among HIF-1α, autophagy and the
conversation of non-stem pancreatic cancer cells into
pancreatic CSCs. Our data showed that conversation
of non-stem pancreatic cancer cells into pancreatic
CSCs resulted from the elevated HIF-1α and activated
autophagy.
Materials and methods
Isolated and culture of pancreatic cancer stem cells and
non-stem pancreatic cancer cells
The pancreatic cancer cell lines (Panc-1 and BxPC-3, pur-
chased from Cell Bank of China Academy of Sciences,
Shanghai, China) were cultured in DMEM-F12 (Gibco,
USA) supplemented with 10% FBS (Gibco, USA), 100 U/mL
penicillin and 100 U/mL streptomycin, in a humidified
atmosphere of 95% air with 5% CO2 at 37°C. Cells were
passaged with 0.25% trypsin/EDTA every 3 days. Se-
veral passage later, cells were seeded and cultured in
serum-free medium consisting of DMEM-F12 medium sup-
plemented with 20 ng/mL epidermal growth factor (Pepro-
tech, Rocky Hill, NJ, USA), 20 ng/mL basic fibroblast growth
factor (Peprotech, USA), B27 (Invitrogen Life Technologies,
Carlsbad, CA, USA), 5 μg/mL insulin, and 2.75 μg/mL trans-
ferrin (Sigma-Aldrich, St. Louis, MO, USA) for eight hours
to recover surface antigens. Then cells were separated by
magnetic sorting column using microbead-conjugated
CD133 antibodies (Miltenyi Biotec Ltd., Surrey, UK).
CD133 positive cells were designated as pancreatic cancer
stem cells whereas CD133 negative cells utilized as non-
stem pancreatic cancer cells.
Non-stem pancreatic cancer cells were cultured over-
night in DMEM-F12 and 5% serum to allow cell attach-
ment and survival. Then, the medium was removed andthe cells cultured in serum-free special medium in order
to perform the experiments in identical.
Intermittent hypoxia environmental exposure
Isolated non-stem pancreatic cancer cells were exposed
to 5 cycles of hypoxia and normoxia. Each cycle con-
sisted of a period of 12 h in hypoxia followed by 12 h re-
covery under normoxia conditions. The medium was
changed during the reoxygenation period. For hypoxia
induction, cells were cultured in hypoxia chambers (Sanyo,
containing 1% O2, 5% CO2, 94% N2.). Nitrogen gas was
supplied to the chambers to induce a controlled reduced
percentage of oxygen. For normoxia, cells were cultured in
incubators containing 5% CO2 and approximately 20% O2.
siRNA knockdown of HIF-1αgene and Chemical treatment
Isolated non-stem pancreatic cancer cells were seeded in
12-well plates. When the cell density reached 50% con-
fluence, the cells were transfected with either 40 nmol/L
a control siRNA that did not specifically target any gene
or HIF-1α-specific siRNA (Suzhou Ribo Life Science
CO., Ltd). Transfections were carried out according to
the manufacturer’s instructions. Then the cells were put
in intermittent hypoxia and normoxia conditions, re-
spectively. Forty-eight hours later, the cells were treated
with 30 μL of 3-MA at the concentration of 10 mM and
continually cultured for 24 h. The treated cells were then
subjected to further experiments.
Western blot analysis
Cells lysates were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to
polyvinylidene fluoride membranes (Merck Millipore,
USA). Membranes were blocked with 5% (w/v) bovine
serum albumin (BSA) in TBST for 1 h at room temperature
and incubated overnight with primary antibodies at 4°C.
They were subsequently incubated with horseradish
peroxidase-conjugated second antibodies. The immunore-
active bands were detected by chemiluminescence (ECL
Plus, Merck Millipore) and relevant blots were quantified by
densitometry using LANE-1D software. For immune detec-
tion, the primary antibody preparations were used as follows:
rabbit-anti-human-Oct-4, rabbit-anti-human-c-MYC, rabbit-
anti-human-HIF-1α, rabbit-anti-human-LC3B, rabbit-anti-
human-Beclin, rabbit-anti-human-β-actin. All antibodies
were obtained from Cell Signaling Technology, Inc. (Boston,
USA). The secondary antibody preparations either anti-
rabbit or anti-mouse were purchased from Boster biotech-
nology company (Wuhan, China).
Real-time PCR
Real-time quantitative PCR was carried out with SYBR
Green qPCR SuperMix (Bio-Rad) using the CFX-96 sys-
tem (Bio-Rad). Total cellular RNA was isolated using
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total RNA using oligo dT and murine Moloney leukemia
virus reverse transcriptase (Toyobo, Japan). Relative
expression levels of the genes were calculated using
the 2−ΔΔCT method.
Flow cytometry analysis
To quantify the converting cells of in non-stem pancre-
atic cancer cells under intermittent hypoxia with orFigure 1 Characterization of morphology and stemness-related markers
cancer cells. (A) Phase-contrast images of the pancreatic cancer stem-like cells
cells displayed fibroblast-like appearance. (B) Oct-4, c-MYC genes expression in
were detected by RT-PCR. (C) Expression of Oct-4, c-MYC proteins in pancreatic
by Western blotting. Data were normalized to β-actin levels. Experiments were
C represents for pancreatic cancer stem-like cells, N represents for non-stem p
expression of the bulk pancreatic cells under the intermittent hypoxia (I
of Oct-4, c-MYC proteins in the bulk pancreatic cells under the intermittent hyp
Data were normalized to β-actin levels. Experiments were repeated three timeswithout siRNA, we measured the expression of the stem
related molecular marker CD133 using anti-CD133- PE
(Miltenyi Biotec Ltd., Surrey, UK). Cells were harvested,
disaggregated to a single cell suspension, and stained as
described previously [17].
Statistical analysis
The significances of differences between groups were an-
alyzed using Student’s t tests. Values of p < 0.05 werebetween pancreatic cancer stem-like cells and non-stem pancreatic
displayed epithelial-like appearance, while non-stem pancreatic cancer
pancreatic cancer stem-like cells and non-stem pancreatic cancer cells
cancer stem-like cells and non-stem pancreatic cancer cells were detected
repeated three times with similar data(* P< 0.05, **P< 0.01, ***P< 0.001).
ancreatic cancer cells. Scale bar equal 50 μm. (D) Oct-4, c-MYC gene
H) and normoxia (N) conditions were detected by RT-PCR. (E) Expression
oxia (IH) and normoxia (N) conditions were detected by Western blotting.
with similar data (* P< 0.05, **P< 0.01, ***P < 0.001).
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formed at least in triplicate.
Results
Characterization of CSC-like cells
The pancreatic cancer stem-like cells were isolated from
the pancreatic cancer cells and their characteristics were
examined. It was easily found that the morphology of
pancreatic cancer stem-like cells displayed epithelial-like
appearance whereas the non-stem pancreatic cancer
cells displayed fibroblast-like appearance (Figure 1A).
Furthermore, the mRNA and protein levels of Oct-4 and
c-MYC were significantly increased in CD133+ pancre-
atic cancer stem-like cells compared to CD133- non-
stem pancreatic cancer cells (Figure 1B and C).
Effective of intermittent hypoxia on maintaining the stem
cell properties of bulk pancreatic cells
It has been reported that hypoxia exposure alone can in-
crease the stem-like cell population. At first, we deter-
mine whether intermittent hypoxia increase the expression
of stem cell associated proteins in the bulk pancreatic cells
which referred to the total cells without sorting by theFigure 2 Intermittent hypoxia reprogrammed non-stem pancreatic can
of non-stem pancreatic cancer cells cultured under intermittent hypoxia (IH
spheres can be detected while the rate of control cells in normoxia was fe
cells under the intermittent hypoxia (IH) and normoxia (N) conditions were
non-stem pancreatic cancer cells under the intermittent hypoxia (IH) an
were normalized to β-actin levels. Experiments were repeated three timmagnetic sorting column using RT-PCR and Western-blot
assay. The results demonstrated that the bulk pancreatic
cells in intermittent hypoxia displayed an increase in tran-
script levels of stem cell markers Oct-4 and c-MYC in
comparison with the cells cultured in normoxia (Figure 1D).
Further, Western-blot had confirmed the up-regulation of
Oct-4 and c-MYC expression in intermittent hypoxia con-
ditioned tumor cells (Figure 1E). Thus, our data confirms
previous studies showing that hypoxia induces stem cell
associated markers including c-myc and Oct4.
Role of intermittent hypoxia in reprogramming non-stem
cancer cells towards a stem-like phenotype
Conventionally, sphere formation assay is thought to be
the method of measuring self-renewal in vitro. In the
study, the isolated non-stem pancreatic cancer cells were
seeded into low adhesion culture plates and treated in
intermittent hypoxia. We found that non-stem pancre-
atic cancer cells cultured under intermittent hypoxia
were able to form spheres (Figure 2A). The non-stem
pancreatic cancer cells under intermittent hypoxia for
72 h significantly increased the expression levels of Oct-4
and c-MYC in comparison to those under normoxiacer cells towards a Stem-like Phenotype. (A) Phase-contrast images
) and normoxia (N) condition. In intermittent hypoxia condition
w. (B) Oct-4, c-MYC gene expression of non-stem pancreatic cancer
detected by RT-PCR. (C) Expression of Oct-4, c-MYC proteins in
d normoxia (N) conditions were detected by Western blotting. Data
es with similar data (**P < 0.01, ***P < 0.001).
Figure 3 Enhanced HIF-1α and autophagy related proteins
express level in non-stem cancer cells under intermittent hypoxia
condition. (A) Isolated non-stem cancer cells were treated with
intermittent hypoxia (IH) and normoxia (N) for the indicated times
(24 h, 48 h and 72 h). Expression of HIF-1α, LC3-II and Beclin proteins
in non-stem pancreatic cancer cells under the intermittent hypoxia
(IH) and normoxia (N) conditions were detected by Western blotting.
Data were normalized to β-actin levels. Experiments were repeated
three times with similar data. (B) Blockade of HIF-1α with siRNA
inhabited autophagy in intermittent hypoxia. Expression of HIF-1α,
LC3-II and Beclin proteins in non-stem pancreatic cancer cells
under the intermittent hypoxia (IH) and normoxic (N) conditions
were detected after transfections by Western blotting.
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tent hypoxic microenvironment not only plays a critical
role in promoting and maintaining the ability of stem-
like cells to self-renew and stemness but also can confer
this capability to the non stem-like population.
Up-regulation of HIF-1α, LC3-II and Beclin express level in
non-stem cancer cells under intermittent hypoxia
condition
Non-stem pancreatic cancer cells were subjected to
intermittent hypoxic conditions for various time periods.
Western-blot assay was employed to assess the role of
intermittent hypoxia in changing the expression level of
HIF-1α, LC3-II and Beclin. Results revealed that the pro-
tein levels of HIF-1α, LC3-II and Beclin were significantly
increased in a time-dependent manner. Compared to nor-
moxic condition, in intermittent hypoxia, the expression
levels of HIF-1α, LC3-II and Beclin were slightly increasedin the first 24 h. HIF-1α exhibited the highest levels after
48 h but LC3-II and Beclin did not reach the maximally
levels until 72 h (Figure 3A). Meanwhile, cell death rate
did not exceed 10% in 72 h treatment (measured by trypan
blue exclusion; data not shown). We next investigated
whether HIF-1α mediates hypoxia-induced autophagy.
The knockdown of HIF-1α with special siRNA significantly
abolished the hypoxia-induced expression of LC3-II and
Beclin (Figure 3B). These observations suggested that
HIF-1α may be required for intermittent hypoxia induced
autophagy.
The intermittent hypoxia induced conversation of non
stem cells into stem-like cells is mediated by HIF-1α and
autophagy
Next, we wondered whether HIF-1α induced autophagy
plays an essential role in conversion of non-stem cells into
stem-like cells. In intermittent hypoxia knockdown of
HIF-1α expression in non-stem pancreatic cancer cells by
siRNA with or without 3-methyl adenine (3-MA), the in-
hibitor of autophagy, it was easily found that the cell
morphology changed a spread fibroblast-like into an
epithelial-like appearance. Inhibition of HIF-1α and
autophagy in intermittent hypoxia significantly reduced
Oct-4 and CD44 levels (Figure 4A), while c-MYC did not
changed (data not shown). By FACS analysis, compared to
the cells under intermittent hypoxia without HIF-1α
siRNA and 3-MA group (32.6 ± 5.10%), the proportion of
CD133+ cells was much smaller in intermittent hypoxia
with HIF-1α siRNA and 3-MA group (4.25 ± 0.47%, a
10-fold decrease in CD133 positive population) and in
normoxia condition group (4.25 ± 0.36%, a 8-fold de-
crease in CD133 positive population; Figure 4B). These
results suggest that HIF-1α mediated autophagy may
be critical for intermittent hypoxia induced conversa-
tion of non-stem cancer cells into stem-like cancer
cells in Panc-1.
Discussion
Accumulating data support the concept that the capabi-
lity of the tumor to grow and propagate is dependent on
a small subset of cells within the tumor, termed cancer
stem cells. CSCs are responsible for tumor formation,
progression, drug resistance, metastasis, and recurrence
[17-20]. More and more studies have shown that CSCs
can be enriched in cell populations obtained from solid
tumors of diverse origins, such as pancreas, breast and
brain.
Although the existence of the cancer stem cells in vari-
ous tumour types had confirmed, the mechanisms regu-
lating their generation and maintenance are still under
debate. In particular, there is a clear need for a more de-
tailed characterization of the microenvironmental cues
that control the tumour stem cell phenotype. Cancer
Figure 4 Blockade HIF-1α and autophagy reduced convertion of non-stem cells into stem-like cells. (A) Western blot analyses for CD44
and Oct-4 protein levels during intermittent hypoxia (IH) or normoxia (N) with or without HIF-1α siRNA and 3-MA. Data were normalized to β-actin
levels. (B) The percentage of CD133+ subpopulation was reduced under intermittent hypoxia condition with HIF-1α siRNA and 3-MA by flow
cytometry. (a) Non-stem pancreatic cancer cells cultured under normoxia without HIF-1α siRNA and 3-MA; (b) Non-stem pancreatic cancer cells
cultured under intermittent hypoxia condition without HIF-1α siRNA and 3-MA; (c) Non-stem pancreatic cancer cells cultured under intermittent hypoxia
condition with HIF-1α siRNA and 3-MA (IH + Inhibitor); (d) IgG-PE antibody was used as a control. The experiment was repeated 3 times and the data
were expressed as mean ± standard deviation. The difference between these three groups was significant, **P < 0.01.
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ronments termed niches to sustain the population.
These niches (vascular proliferations, hypoxia/necrosis)
represent the hallmarks of malignant tumors [21,22].
Pancreatic cancer is characterized by intratumoral hypo-
vascularity. High levels of hypoxia in pancreatic cancers
can be detected intraoperatively with an oxygen micro-
electrode [23]. More and more evidences confirmed that
environmental signals from hypoxic and vascular niches
were crucially involved in tumour stem cell maintenance
[24-27]. Intermittent hypoxia, which is characterized by
cyclic periods of hypoxia and re-oxygenation, occurs intumor cells that are dependent on tumor blood vessels
having intermittent perfusion fluctuations in blood flow.
With the aim to more closely mimic solid tumors in
vivo, we selected a sequence of hypoxic and normoxic
intervals of 12 h, namely intermittent hypoxia in this
study. One of the open questions is whether hypoxia
merely support the self-renewal of CSCs or can also
control stem cell plasticity and reprogram the non-stem
cancer cells population into CSCs. Recently, several re-
searchers reported that differentiated cancer cells can
convert to stem-like cells to maintain equilibrium. In
view of our results in vitro that the fraction of CD133+
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CD133- cells can reacquire stem cell properties under
intermittent hypoxia. Our results support that non-
stem cancer cells could be converted into stem-like
cells in the pancreatic cancer cells under intermittent
hypoxia.
Tumour hypoxia activates a complex set of cellular re-
sponses that are differentially mediated by members of
the HIF family. Recent reports have identified new mo-
lecular programs by which HIF may regulate cellular dif-
ferentiation and self renewal, identifying critical stem
cell regulators such as Oct4, c-MYC as direct or indirect
HIF targets [28-31]. HIF-1α which plays a key role in
cancer progression by regulating a number of processes
is the best characterized among the transcriptional regula-
tors under hypoxia. In this study, the ablation of HIF-1α
with siRNA decreased cells transformation in intermittent
hypoxia. Our data supported an additional function of
HIF-1α in controlling stem cell plasticity and reprogram-
ming the non-stem cancer cells population into stem-like
cells. These results are consistent with a recent report
using human glioma cell lines.
Autophagy is an evolutionarily conserved mechanism
involving the formation of autophagosomes that seques-
ter cytoplasmic macromolecules and organelles before
fusion with the lysosomal compartment. Autophagy was
detected by three sets of assays: Western blot of LC3-II
protein levels that measures autophagy flux, staining
with acridine orange to detect AVOs by fluorescent mi-
croscopy and flow cytometry and observation and quan-
tification of green fluorescent protein (GFP)-LC3 puncta
by fluorescent microscopy that detects autophagosomes
[32-35]. In this study, we used the first assay that mea-
sured the protein levels of LC3-II and Beclin1. LC3-II
plays an important role in the autophagosome forma-
tion. Beclin1 suggests an important role of this protein
in cell survival and death relying on the cellular context.
Until recently, it remains controversial as to whether au-
tophagy acts primarily as a cell survival or cell death
pathway. During hypoxia, autophagy facilitates the re-
moval of ROS-altered mitochondria, reduces oxidative
stress and promotes cell survival, but it could also be
considered as a pro-tumor mechanism. The present
study demonstrated that in the early stagy of intermit-
tent hypoxia autophagy did not only as a survival
mechanism under hypoxic conditions but also give a
hand in converting the non-stem cancer cells population
into stem-like cells. In addition, our results confirm that
HIF-1α is a key mechanism in the activation of hypoxia-
induced autophagy. But the exact mechanism need further
investigation. Since pancreatic carcinoma has a pro-
nounced hypoxic tumour microenvironment and the
levels of hypoxia and autophagy are both independent
factors, it is of greatly interest in clinical.Conclusion
Our results clearly uncover one of the crucial phenome-
nons of conversation between non cancer stem cells and
cancer stem cells in hypoxia and show how HIF-1α and
autophagy impact this process in Panc-1. In fact, the
other pancreatic cell line (BxPC-3) was also used in this
study. Similar results were obtained (data not shown).
These results provide an important framework for the
development of novel and promised therapeutic strategy
that not only more effective and specific anti-CSC the-
rapies but also including the alteration of components of
the tumor niche. It may serve as a critical therapeutic
paradigm to investigate for the treatment of cancer with
the ultimate hope of bringing long-term clinical benefits
to the patients.
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